Trial Profile
Immunogenicity and Safety of a 13-valent pneumococcal conjugate vaccine in paediatric oncology patients
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 21 Sep 2017
Price :
$35
*
At a glance
- Drugs Pneumococcal 13-valent CRM197 vaccine conjugate (Primary)
- Indications Pneumococcal infections
- Focus Therapeutic Use
- 11 Jul 2017 Status changed from recruiting to completed, according to the results published in the Cancer.
- 19 Apr 2013 New trial record